The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome

<h3>Background</h3><p dir="ltr">Atorvastatin has been shown to improve cardiovascular risk (CVR) indices in women with polycystic ovary syndrome (PCOS). Low-grade chronic inflammation of adipose tissue may link PCOS and adverse CVR. In pro-inflammatory states such as PCOS...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Thozhukat Sathyapalan (704787) (author)
مؤلفون آخرون: James P. Hobkirk (18140275) (author), Zeeshan Javed (9975180) (author), Sean Carroll (1723798) (author), Anne-Marie Coady (18140278) (author), Philip Pemberton (18140281) (author), Alexander Smith (326930) (author), Katherine Cianflone (155973) (author), Stephen L. Atkin (6684368) (author)
منشور في: 2019
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513521765580800
author Thozhukat Sathyapalan (704787)
author2 James P. Hobkirk (18140275)
Zeeshan Javed (9975180)
Sean Carroll (1723798)
Anne-Marie Coady (18140278)
Philip Pemberton (18140281)
Alexander Smith (326930)
Katherine Cianflone (155973)
Stephen L. Atkin (6684368)
author2_role author
author
author
author
author
author
author
author
author_facet Thozhukat Sathyapalan (704787)
James P. Hobkirk (18140275)
Zeeshan Javed (9975180)
Sean Carroll (1723798)
Anne-Marie Coady (18140278)
Philip Pemberton (18140281)
Alexander Smith (326930)
Katherine Cianflone (155973)
Stephen L. Atkin (6684368)
author_role author
dc.creator.none.fl_str_mv Thozhukat Sathyapalan (704787)
James P. Hobkirk (18140275)
Zeeshan Javed (9975180)
Sean Carroll (1723798)
Anne-Marie Coady (18140278)
Philip Pemberton (18140281)
Alexander Smith (326930)
Katherine Cianflone (155973)
Stephen L. Atkin (6684368)
dc.date.none.fl_str_mv 2019-06-01T00:00:00Z
dc.identifier.none.fl_str_mv 10.3389/fendo.2019.00394
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/The_Effect_of_Atorvastatin_and_Subsequent_Metformin_on_Adipose_Tissue_Acylation-Stimulatory-Protein_Concentration_and_Inflammatory_Biomarkers_in_Overweight_Obese_Women_With_Polycystic_Ovary_Syndrome/25390657
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
atorvastatin
acylation-stimulating-protein
interleukin-6
monocyte-chemoattractant-protein-1
adipose tissue
PCOS
dc.title.none.fl_str_mv The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background</h3><p dir="ltr">Atorvastatin has been shown to improve cardiovascular risk (CVR) indices in women with polycystic ovary syndrome (PCOS). Low-grade chronic inflammation of adipose tissue may link PCOS and adverse CVR. In pro-inflammatory states such as PCOS, spontaneous activation of the alternative pathway of complement results in increased generation of acylation stimulating protein (ASP) from adipocytes irrespective of body mass index.</p><h3>Methods</h3><p dir="ltr">The objective of this study was to determine the effect of atorvastatin on markers of adipose tissue dysfunction and inflammation; acylation-stimulating-protein (ASP), interleukin-6 (IL-6), and monocyte-chemoattractant-protein-1 (MCP-1) in PCOS. This was a randomized, double-blind, placebo-controlled study where 40 medication-naive women with PCOS and biochemical hyperandrogenaemia were randomized to either atorvastatin 20 mg daily or placebo for 12 weeks. Following the 12 week randomization; both group of women with PCOS were subsequently started on metformin 1,500 mg daily for further 12 weeks to assess whether pre-treatment with atorvastatin potentiates the effects of metformin on markers of adipose tissue function We conducted a post-hoc review to detect plasma ASP and the pro-inflammatory cytokines IL6 and MCP-1 before and after 12 and 24 weeks of treatment.</p><h3>Results</h3><p dir="ltr">There was significant reduction in ASP (156.7 ± 16.2 vs. 124.4 ± 14.8 ng/ml p <0.01), IL-6 (1.48 ± 0.29 vs.0.73 ± 0.34 pg/ml p = 0.01) and MCP-1 (30.4 ± 4.2 vs. 23.0 ± 4.5 pg/ml p = 0.02) after 12 weeks of atorvastatin that was maintained subsequently with 12 weeks treatment with metformin. There was a significant positive correlation between ASP levels with CRP (p < 0.01), testosterone (p < 0.01) and HOMA-IR (p < 0.01); IL-6 levels with CRP (p <0.01) and testosterone (p < 0.01) and MCP-1 with CRP (p < 0.01); testosterone (p < 0.01) and HOMA-IR (p < 0.02).</p><h3>Conclusions</h3><p dir="ltr">This post-hoc analysis revealed that 12 weeks of atorvastatin treatment significantly decreased the markers of adipose tissue dysfunction and inflammation, namely ASP, IL-6 and MCP-1 in obese women with PCOS. Changes in adipose tissue markers were significantly associative with substantial improvements in HOMA-IR, testosterone and hs-CRP levels.</p><p><br></p><p dir="ltr">ISRCTN Number: ISRCTN24474824</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Endocrinology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fendo.2019.00394" target="_blank">https://dx.doi.org/10.3389/fendo.2019.00394</a></p>
eu_rights_str_mv openAccess
id Manara2_18ec6bea8f5745dfce61541036d18988
identifier_str_mv 10.3389/fendo.2019.00394
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/25390657
publishDate 2019
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary SyndromeThozhukat Sathyapalan (704787)James P. Hobkirk (18140275)Zeeshan Javed (9975180)Sean Carroll (1723798)Anne-Marie Coady (18140278)Philip Pemberton (18140281)Alexander Smith (326930)Katherine Cianflone (155973)Stephen L. Atkin (6684368)Biomedical and clinical sciencesClinical sciencesatorvastatinacylation-stimulating-proteininterleukin-6monocyte-chemoattractant-protein-1adipose tissuePCOS<h3>Background</h3><p dir="ltr">Atorvastatin has been shown to improve cardiovascular risk (CVR) indices in women with polycystic ovary syndrome (PCOS). Low-grade chronic inflammation of adipose tissue may link PCOS and adverse CVR. In pro-inflammatory states such as PCOS, spontaneous activation of the alternative pathway of complement results in increased generation of acylation stimulating protein (ASP) from adipocytes irrespective of body mass index.</p><h3>Methods</h3><p dir="ltr">The objective of this study was to determine the effect of atorvastatin on markers of adipose tissue dysfunction and inflammation; acylation-stimulating-protein (ASP), interleukin-6 (IL-6), and monocyte-chemoattractant-protein-1 (MCP-1) in PCOS. This was a randomized, double-blind, placebo-controlled study where 40 medication-naive women with PCOS and biochemical hyperandrogenaemia were randomized to either atorvastatin 20 mg daily or placebo for 12 weeks. Following the 12 week randomization; both group of women with PCOS were subsequently started on metformin 1,500 mg daily for further 12 weeks to assess whether pre-treatment with atorvastatin potentiates the effects of metformin on markers of adipose tissue function We conducted a post-hoc review to detect plasma ASP and the pro-inflammatory cytokines IL6 and MCP-1 before and after 12 and 24 weeks of treatment.</p><h3>Results</h3><p dir="ltr">There was significant reduction in ASP (156.7 ± 16.2 vs. 124.4 ± 14.8 ng/ml p <0.01), IL-6 (1.48 ± 0.29 vs.0.73 ± 0.34 pg/ml p = 0.01) and MCP-1 (30.4 ± 4.2 vs. 23.0 ± 4.5 pg/ml p = 0.02) after 12 weeks of atorvastatin that was maintained subsequently with 12 weeks treatment with metformin. There was a significant positive correlation between ASP levels with CRP (p < 0.01), testosterone (p < 0.01) and HOMA-IR (p < 0.01); IL-6 levels with CRP (p <0.01) and testosterone (p < 0.01) and MCP-1 with CRP (p < 0.01); testosterone (p < 0.01) and HOMA-IR (p < 0.02).</p><h3>Conclusions</h3><p dir="ltr">This post-hoc analysis revealed that 12 weeks of atorvastatin treatment significantly decreased the markers of adipose tissue dysfunction and inflammation, namely ASP, IL-6 and MCP-1 in obese women with PCOS. Changes in adipose tissue markers were significantly associative with substantial improvements in HOMA-IR, testosterone and hs-CRP levels.</p><p><br></p><p dir="ltr">ISRCTN Number: ISRCTN24474824</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Endocrinology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fendo.2019.00394" target="_blank">https://dx.doi.org/10.3389/fendo.2019.00394</a></p>2019-06-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fendo.2019.00394https://figshare.com/articles/journal_contribution/The_Effect_of_Atorvastatin_and_Subsequent_Metformin_on_Adipose_Tissue_Acylation-Stimulatory-Protein_Concentration_and_Inflammatory_Biomarkers_in_Overweight_Obese_Women_With_Polycystic_Ovary_Syndrome/25390657CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/253906572019-06-01T00:00:00Z
spellingShingle The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
Thozhukat Sathyapalan (704787)
Biomedical and clinical sciences
Clinical sciences
atorvastatin
acylation-stimulating-protein
interleukin-6
monocyte-chemoattractant-protein-1
adipose tissue
PCOS
status_str publishedVersion
title The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
title_full The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
title_fullStr The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
title_full_unstemmed The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
title_short The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
title_sort The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
topic Biomedical and clinical sciences
Clinical sciences
atorvastatin
acylation-stimulating-protein
interleukin-6
monocyte-chemoattractant-protein-1
adipose tissue
PCOS